|
Model Number N/A |
Device Problem
No Apparent Adverse Event (3189)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 05/20/2019 |
Event Type
malfunction
|
Manufacturer Narrative
|
The initial sample was recovered and checked by the customer and found to contain fibrin.After removing the fibrin, the sample was reprocessed and a positive result was obtained.Siemens healthcare diagnostics is investigating this issue.The interpretation of results section of the instructions for use states: "results of this assay should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings." the limitations section of the instructions for use states: "all in vitro assays can generate erroneous results, both clinically false positive results (test results suggesting a condition that is absent) and clinically false negative results (test results failing to identify a condition that is present).There are many possible causes for these types of discordant results.Erroneous results may occur due to interference from identifiable serum constituents or patient-specific serum constituents.".
|
|
Event Description
|
A false negative atellica im total hcg (thcg) result was obtained on a patient sample.This result was reported and questioned by the physician.The patient was retested with a different sample, and the result was positive.Patient treatment was not prescribed or altered.There was no report of adverse health consequences due to the discordant total hcg result.
|
|
Manufacturer Narrative
|
Siemens filed the initial mdr on june 21, 2019.Corrected data: patient sample 1 date tested was incorrectly recorded in the initial mdr (section b6) as on (b)(6) 2019 and should have been on (b)(6) 2019.Additional data from 08/14/2019: patient (b)(6), female, 37 years old, underwent thcg testing on (b)(6) 2019.Sample was processed on atellica im ih00576 and generated a result of 2.0miu/ml.This result was released to the doctor who questioned the result.On (b)(6) 2019, another sample from the same patient was further tested (b)(6).This sample was processed in a supporting laboratory and a result 1000miu/ml was obtained and after dilution (x200) 4742 miu/ml.The primary sample was recovered (b)(6) and checked by the customer to contain fibrin / clot.After removing the clot, the sample was reprocessed on (b)(6) 2019 and yielded a result 1000miu/ml.This issue is a non-reproducible false low thcg result due to fibrin.No product performance issue has been identified with atellica total hcg assay.The system clot detection is based on a change in pressure and there is a possibility that the clot could impede the pipetting but not cause a large enough pressure change to trigger the error.No product problem has been identified.Investigation complete.No further evaluation of the device is required.
|
|
Search Alerts/Recalls
|
|
|